BioMed Research International / 2015 / Article / Tab 1

Research Article

Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study

Table 1

Baseline patient and tumor characteristics.

Characteristic = 30

Gender, N (%)
 Male22 (73.3)
 Female8 (26.7)
Age,1 years
 Median (range)57 (29–80)
Tumor type, N (%)
 Pancreatic cancer22 (73.3)
 Biliary cancer8 (26.7)
Performance status (ECOG),2   (%)
 01 (3.3)
 118 (60.0)
 210 (33.3)
 Unknown1 (3.3)
Number of lines of therapy for advanced disease before MP,3   (%)
 119 (63.3)
 27 (23.3)
 32 (6.7)
 42 (6.7)

At diagnosis.
2At MP.
3For 6 patients who progressed on adjuvant therapy, their adjuvant regimen was considered first-line treatment for advanced disease.
ECOG: Eastern Cooperative Oncology Group; MP: molecular profiling.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.